about
Potassium channel openers as potential therapeutic weapons in ion channel disease.Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?Modulation of potassium channels as a therapeutic approach.Treatment options and patient perspectives in the management of fibromyalgia: future trends.Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies?Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States.Potential drug therapies for the treatment of fibromyalgia.Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels.Rubidium efflux as a tool for the pharmacological characterisation of compounds with BK channel opening properties.A qualitative exploration of the experiences of living with and being treated for fibromyalgia.Large conductance Ca(2+)-activated K(+) channel (BKCa) activating properties of a series of novel N-arylbenzamides: Channel subunit dependent effects.A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.The role of c-kit-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats.Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: Effect of potassium channel modulatorsEffects of the divalent cations nickel and cadmium on contractions of rat aorta to endothelin-1SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat(-)-Bay K 8644 liberates a contractant factor from the endothelium of the rat aortaEffects of Ca2+ antagonists and K+-channel activators on K+-induced contractions in the rat aortaContractions of rat aorta to endothelin are sensitive to nickel and cadmium ions but not nicardipine or omega-conotoxinBeneficial treatment of fibromyalgiaFlupirtine Is an Effective Analgesic: Is the Associated Rare Liver Injury a Limiting Factor to Its Use?
P50
Q33865181-4A095FEF-B7F7-4C99-9EA4-578886C17A24Q34974870-D418BFC0-AEF6-4B60-AC1C-54890C75ED49Q36393576-66796784-1CFC-4B3B-98F1-FF2CA2361296Q37106939-F4794107-E05F-4DB3-A7B2-026FB0E37485Q37135913-2A8F6E76-AF62-4382-B09B-E5D1C863FF36Q37886173-242D33D8-8991-45B0-AA06-94DEBC35591BQ38857241-E5FAAA81-BBBE-43EF-B490-0682BC0479FCQ39216830-362DABFC-A5FE-4156-8087-C299B318C7C5Q39919258-C8AB84BE-2B2B-49C8-A3C6-4F034F9F8D6DQ49591874-20D4ABCF-4D9F-4AC3-9F0D-52D03DAEA425Q50960761-30F15FEB-1EA3-4A91-AA8A-F962143BF108Q52641632-228353E7-07B0-4396-90F8-42231BF79D57Q54654140-12B7E986-A2E3-45C8-8C5F-480AB51B8AA0Q59685400-19A1E16A-ED73-4053-852C-E6F670F8BCEDQ68027487-93FCE601-7887-4F8F-9685-6D845AF594CCQ68294393-BB9ECBAF-99AE-4B19-8540-A1F3C5F03156Q69126824-C48585E7-F036-4984-A481-DC8A56A5757BQ69127085-402B71F2-A0B8-48A4-B9EE-EAABD18FDF6DQ69564963-63E21E16-37AA-4A34-8978-DA98DF16F3E4Q84834702-3851DA52-7177-46CD-A5E2-62BFD9BC6249Q88714774-9C03968F-6DBE-4B0F-8FC0-492BCB8CC25A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kim Lawson
@ast
Kim Lawson
@en
Kim Lawson
@es
Kim Lawson
@nl
type
label
Kim Lawson
@ast
Kim Lawson
@en
Kim Lawson
@es
Kim Lawson
@nl
prefLabel
Kim Lawson
@ast
Kim Lawson
@en
Kim Lawson
@es
Kim Lawson
@nl
P106
P1153
7103032530
P31
P496
0000-0002-5458-1897